Your browser doesn't support javascript.
loading
Validity and reliability measures of the Swedish Karolinska version of the Edinburgh Cognitive and Behavioral ALS Screen (SK-ECAS).
Foucher, Juliette; Winroth, Ivar; Lovik, Anikó; Sennfält, Stefan; Pereira, Joana B; Fang, Fang; Lule, Dorothee; Andersen, Peter M; Ingre, Caroline.
Afiliação
  • Foucher J; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Winroth I; Department of Neurology, ME Neurology, Karolinska University Hospital, Stockholm, Sweden.
  • Lovik A; Department of Clinical Sciences, Neuroscience, Faculty of Medicine, Umeå University, Umeå, Sweden.
  • Sennfält S; Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Pereira JB; Methodology and Statistics Unit, Institute of Psychology, Leiden University, Leiden, The Netherlands, and.
  • Fang F; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Lule D; Department of Neurology, ME Neurology, Karolinska University Hospital, Stockholm, Sweden.
  • Andersen PM; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Ingre C; Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Article em En | MEDLINE | ID: mdl-37519256
ABSTRACT

OBJECTIVE:

Cognitive and behavioral impairment is observed in up to 50% of patients with amyotrophic lateral sclerosis (ALS). The Edinburgh Cognitive and Behavioral ALS Screen (ECAS) is a 5-domain screening tool customized for quick cognitive screening in patients with ALS. Although the ECAS is available in Swedish at the Karolinska University Hospital (SK-ECAS), it has not yet been validated in Sweden stressing the need to assess validity and reliability of the SK-ECAS Version A.

METHODS:

The study included 176 patients with ALS or other motor neuron disease diagnosed between September 2017 and October 2021 at the Karolinska ALS Clinical Research Center in Stockholm, Sweden, and 35 age-matched healthy control subjects. SK-ECAS was validated against the Montreal Cognitive Assessment (MoCA) and optimal cutoffs, receiver operating characteristic (ROC) curve and area under the curve (AUC) were calculated.

RESULTS:

We identified an optimal cutoff of 108 for the SK-ECAS total score and 82 for the SK-ECAS ALS-specific score to detect cognitive impairment. The SK-ECAS showed good performance in indicating abnormal cognition with an AUC of 0.73 for SK-ECAS ALS-specific score and 0.77 for SK-ECAS total score. There was good internal consistency with a Cronbach's alpha of 0.79.

CONCLUSIONS:

This study demonstrates good validity and reliability indices for SK-ECAS Version A for the detection of cognitive impairment in newly diagnosed ALS patients.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Amyotroph Lateral Scler Frontotemporal Degener Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suécia

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Amyotroph Lateral Scler Frontotemporal Degener Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suécia